Scientific Excellence Award 2018 (now closed for nominations)
“The CSATVB Scientific Excellence Award” is sponsored by the Canadian Society for Atherosclerosis, Thrombosis and Vascular Biology. An award of $1000 is given to an active researcher for consistently outstanding and innovative research in the areas of atherosclerosis, thrombosis and/or vascular biology. The award is open to Canadian citizens or landed immigrants in Canada who are faculty members of a Canadian university or are staff members of a recognized Canadian research institute or equivalent.
The deadline for receipt of letters of nominations is October 3, 2017. The letter should explain why the nominee is deserving of the award and include an up-to-date full CV of the candidate. Please send nominations (electronically) to:
Dr. Avrum I. Gotlieb
Chair, CSATVB Scientific Excellence Award
Professor, Department of Laboratory Medicine and Pathobiology
Faculty of Medicine, University of Toronto
Medical Sciences Building, 1 Kings College Circle, Room 6231
Toronto, Ontario M5S 1A8 Canada
The award will consist of a cheque for $1000, a commemorative plaque, and free membership to CSATVB for 1 year. The awardee is expected to deliver a keynote scientific lecture at annual CSATVB meeting at the XVIIIth International Symposium on Atherosclerosis in Toronto, June 9-12 2018.
Nominees for this award are now being sought. Please distribute widely and consider making a nomination yourself. All nomination letters will be acknowledged.
Previous CSATVB Scientific Excellence Award Winners
Dr. Rob Hegele, Distinguished University Professor, Western University, London, Ontario
Dr. Gary Lewis, Professor, University of Toronto, Ontario
Dr. Gary Lewis, is the recipient of the CSATVB Scientific Excellence Award (2016) and will present at the CCC/CSATVB on October 24, 2016 from 10-10:30am.
The Lewis lab has had a long interest in the mechanisms of various aspects of diabetic dyslipidemia, including postprandial lipemia, HDL lowering and hypertriglyceridemia. They have also had a long standing interest in the interaction between the free fatty acids and pancreatic beta cell dysfunction. Previously they have performed both animal and human mechanistic studies but currently are focusing exclusively on the human. In 2002, working in close collaboration with Dr. Khosrow Adeli (UofT), the Lewis lab made the novel observation that the intestine, in additon to the liver, overproduces lipoprotein overproduction in insulin resistance and Type 2 diabetes. The Lewis lab perform integrative, physiological studies in humans, attempting to determin the regulation of intestinal and hepatic lipoprotein particle production by hormones, nutrients and pharmacological agents.
Dr. Jean Davignon, IRCM Emeritus Professor, Institut de recherches cliniques de Montréal
Dr. Jean Davignon is the 6th recipient of the CSATVB Scientific Excellence Award (2013) and will present at the CCC/CSATVB (Vascular 2013) in October 2013 in Montreal.
Jean Davignon has been Director of the Hyperlipidemia and Atherosclerosis Research Unit at the Institut de recherches cliniques de Montréal (IRCM) since 1967, Emeritus Physician at Hôtel-Dieu Hospital in Montreal, Professor at the Faculty of Medicine at the Université de Montréal and Adjunct Professor in the Department of Experimental Medicine at McGill University. He was appointed Emeritus Researcher at the IRCM in 2009.
His research focuses on the characterization, pathogenesis and treatment of hereditary dyslipidemias, on the atherogenic potential of plasma lipid and non-lipid biomarkers and the role of gene-gene and gene-environment interactions in the causation of cardiovascular diseases. His work encompassing nutritional, genetic, metabolic, pharmacogenomic and molecular aspects has resulted in the publication of 343 scientific papers, 379 abstracts, 59 book chapters and 10 books including an Atlas on Hyperlipidemias (2007).
He is a founding member of the Canadian Atherosclerosis Society, the Canadian Association for Familial Hypercholesterolemia and the Canadian Institute of Academic Medicine. He is a member of numerous scientific and academic societies, notably the Academy of Sciences of the Royal Society of Canada. He is also a member of many national and international committees and is active on the editorial boards of several scientific journals. He organized and presided the Xth International Symposium on Atherosclerosis, held in Montréal in October 1994, and he was a member of the Governing Council of the Canadian Institutes of Health Research from its foundation in 2000 to 2002. He is a member of the Canadian Heart Health Strategy and Action Plan Steering Committee (2006-2009).
Jean Davignon is a recipient of the FNG Starr Award of the Canadian Medical Association (1993), the Scientific Career Award of the Association des médecins de langue française du Canada (1996), the Prix du Québec Wilder Penfield (2000), the Prix Michel Sarrazin for his contribution to clinical research (2001), the Distinguished Service Award from the Canadian Society for Clinical Investigation (2006) and the Distinguished Clinical Scientist Award from the Midwest Lipid Association, Kansas City, USA (2006). He also received a doctorate Honoris Causa from Université Paul Sabatier, Toulouse, France (1992), and the Grande Médaille d’Or du Centenaire from the Institut Pasteur of Lille, France (1994). He was named Officer of the Order of Canada in 1995 and Grand Officier de l’Ordre national du Québec in 2006. The Jean Davignon Distinguished Cardiovascular and Metabolic Research Award, sponsored by Pfizer, was created in 2006.
Dr. Ruth McPherson, University of Ottawa Heart Institute, Ottawa, Ontario
Dr. Ruth McPherson is the 5th recipient of the CSATVB Scientific Excellence Award (2012) and will present at the CCC/CSATVB in October 2012 in Toronto.
Dr McPherson is a Canadian physician scientist. Her research has evolved from the study of lipoprotein metabolism to the genetics and genomics of coronary artery disease (CAD). She carried out some of the earliest studies on cholesteryl ester transfer protein (CETP), including regulation of gene expression and plasma kinetics and subsequently identified CETP as a novel receptor for selective uptake of HDL-CE in adipocytes and liver. Other studies focused on the intracellular trafficking of hepatocyte SR-BI during selective uptake and in response to cholesterol, providing new insights into the final pathway of reverse cholesterol transport. She also made the original observation that endocytosis is enhanced in ABCA1 deficient fibroblasts and that in both macrophages and fibroblasts, that secretory vesicular transport from the Golgi to the plasma membrane increased 2-fold during apo A-I mediated cholesterol efflux, a process which requires ABCA1. Dr McPherson’s more recent studies have been focused on rare and common genetic variants contributing to coronary artery disease risk. She was co-director of the first genome wide association study (GWAS) to identify the chromosome 9p21 locus for CAD (Science 2007) and more recently, 13 additional novel genetic markers of CAD risk as part of the CARDIoGRAM consortium (Nature Genetics 2011). Dr McPherson lists more than 135 full publications. A major current objective of her laboratory is to understand the functional relationship of genetic variants to atherosclerosis using bioinformatic, molecular and cellular assays.
Dr. Khosrow Adeli, Clinical Biochemistry, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, Ontario
Dr.Khosrow Adeli is the 4th recipient of the CSATVB Scientific Excellence Award (2011) and presented at the Oral Session III at the CCC/CSATVB in October 2011 in Vancouver.
Growing evidence suggests that whole body lipid homeostasis is maintained via a complex network of hormonal and neural mechanisms and communication links between the CNS and key tissues including the liver and intestine. The liver and intestine have complementary and coordinated roles in lipoprotein metabolism. Despite their highly specialized functions, assembly and secretion of triglyceride-rich lipoproteins (TRL; apoB100-containing VLDL in the liver and apoB48-containing chylomicrons in the intestine) are regulated by many of the same hormonal, in ammatory, nutrient and metabolic factors. Both the liver and intestine play important roles in the pathophysiology of dyslipidemia in diabetes and other insulin resistant states. In the presence of compromised metabolic conditions, such as insulin resistance, type 2 diabetes and metabolic syndrome, a cluster of dyslipidemic characteristics are present, including hypertriglyceridemia, low highdensity lipoprotein (HDL) and small, dense low-density lipoprotein (LDL) particles. In insulin resistance, overproduction of TRL by both liver and intestine is a prominent component of and underlies other features of a complex dyslipidemia and increased risk of atherosclerosis. The intestine is gaining increasing recognition for its importance in a ecting wholebody lipid homeostasis, in part through its interaction with the liver. Recent studies indicate a critical role for gut peptides and neuroendocrine signals in regulating lipid absorption and intestinal lipoprotein production. This lecture will aim to integrate recent advances in our understanding of these processes and discuss the critical factors that coordinate lipid homeostasis in normal and insulin resistant states.